Could a gut bacteria transplant save lungs from sepsis?

NCT ID NCT07342205

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether transplanting healthy gut bacteria (fecal microbiota) can help people with acute lung injury caused by sepsis. Sepsis triggers severe inflammation that often damages the lungs, and current treatments are limited. The trial will compare standard care plus a placebo against standard care plus the bacteria transplant in 60 adults. Researchers will measure oxygen levels, survival at 28 days, and ICU stay length.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
human-derived active intestinal bacterial liquid (fecal microbiota transplant)
What this could lead to
If it works, this could offer a new treatment to reduce deaths and improve recovery in sepsis patients with lung injury.
What could go wrong
This is an early phase 2/3 trial with only 60 people. The treatment may not work better than placebo, and risks like infection or gut issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LUNG INJURY(ALI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Putuo Hospital, Shanghai University of Traditional Chinese Medicine

    RECRUITING

    Shanghai, Putuo, 421000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.